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Lupus nephritis (LN) is a major cause of morbidity and
mortality in patients with systemic lupus erythematosus.
Although the use of aggressive immunosuppression has
improved both patient and renal survival over the past
several decades, the optimal treatment of LN remains
challenging. Improved outcomes have come at the expense
of significant adverse effects owing to therapy. Moreover
with long-term survival, the chronic adverse effects of
effective therapies including risk of malignancy,
atherosclerosis, infertility, and bone disease all become more
important. Finally, some patients fail to achieve remission
with standard cytotoxic therapy and others relapse when
therapy is reduced. For these reasons, recent clinical trials
have attempted to define alternate treatment protocols that
appear to be efficacious in achieving and maintaining
remission, but with less toxicity than standard regimens. This
paper discusses established and newer treatment options for
patients with proliferative and membranous LN, with an
emphasis on the results of these recent clinical trials. We also
review the experimental and human data regarding some of
the novel targeted forms of therapy that are under
investigation and in different phases of clinical trials.
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Renal involvement is a frequent and serious complication of
systemic lupus erythematosus (SLE). It contributes both
directly to morbidity and mortality of the patients as well as
indirectly through side effects of therapy directed at the renal
lesions. Although survival has improved dramatically in
patients with focal and diffuse proliferative lupus nephritis
(LN), until recently ‘standard’ treatment for severe disease
was associated with multiple potential adverse toxicities.
Newer treatments for severe LN show promise of equivalent
efficacy but less toxicity as well as the potential to treat
resistant disease.
Patient and renal survival of SLE patients has improved
considerably over the past few decades, in part, due to earlier
recognition of renal disease, aggressive immunosuppression,
and prevention of complications of therapies.1–3 The optimal
immunosuppressive regimen for proliferative LN remains the
subject of research, clinical trials, and intense debate. Until
recently, the majority of nephrologists and rheumatologists
relied on one ‘standard’ approach to the treatment of severe
LN based upon a series of trials at the National Institutes of
Health.4–7 Recent well-performed, randomized controlled
National Institutes of Health trials proved the efficacy of a
regimen consisting of six monthly pulses of intravenous (i.v.)
cyclophosphamide (CYC) (0.5–1 g/m2) followed by sub-
sequent i.v. CYC pulses every 3 months for 2 years. This
regimen was shown to have fewer flares and relapses and
better renal survival than a shorter regimen of six monthly
treatments without follow-up doses. Subsequent studies at
the National Institutes of Health proved that concomitant i.v.
methylprednisolone with monthly pulse i.v. CYC5,6 was more
effective in the short term than either therapy alone. In
longer follow-up of the same population, the combination
regimen had no greater toxicity than CYC alone, but far
superior renal outcomes. Although clearly effective, this
regimen is associated with both short-term and long-term
adverse effects, including increased risk of severe infections,
gonadal damage,5,8,9 and malignancy.10 A significant propor-
tion of patients (up to 22%) fail to achieve remission with
this regimen or relapse after treatment and some patients still
progress to end-stage renal disease.11
In view of this, there has been increasing attention on
developing alternate therapies that promptly and effectively
induce remission, prevent relapse, and maximize patient and
renal survival while incurring the least toxicity. Akin to
oncologists, nephrologists are now focusing on the concept of
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‘induction treatment’ with vigorous initial therapies, fol-
lowed by ‘maintenance treatment’ with lower doses of less
toxic regimens. Such strategies include minimizing the use of
CYC with lower dosages, use of sequential therapies with
different immunosuppressive agents, and eliminating expo-
sure to CYC entirely with use of alternative agents. Myco-
phenolate mofetil (MMF), rituximab, and newer biologics
are all being studied in controlled, randomized trials.
However, at present no single regimen has become the new
standard of care for treatment of LN. Many physicians are
cautious about using newer therapies until solid, long-term
evidence shows that the alternate treatment is superior and/
or less toxic. Furthermore, it has been difficult for many
clinicians to integrate the results of multiple prospective and
retrospective studies recently performed in different popula-
tions into their general practice.
The aim of this review is to update the reader on the
results of several pivotal clinical trials, which lend strong
support to the use of alternative induction and maintenance
treatment regimens for proliferative LN. It will emphasize the
potential benefits as well as the short comings of these
studies. Recent data on treatment of membranous lupus
nephropathy will be discussed. A brief overview of the pro-
mising novel biologic therapies currently under investigation
will be included.
INDUCTION TRIALS
The Euro-Lupus Nephritis Trial, a European-based multi-
center prospective trial, was a head-to-head comparison of
low-dose to ‘conventional’ high-dose i.v. CYC for severe
active LN.12 Ninety patients were randomized to either high-
dose CYC (six monthly i.v. pulses of 0.5–1 g/m2 followed by
two quarterly pulses) or low-dose CYC (fixed i.v. pulses of
500 mg given every 2 weeks for a total of six doses). Following
CYC, both groups received oral azathioprine (AZA) as
maintenance therapy. The majority of patients was Whites
and had class IV diffuse proliferative lupus nephritis (DPLN).
At 41 months, there were no significant differences in the
primary end point, cumulative probability of treatment
failure, between the high- and low-dose treatment arms (20
vs 16%, respectively). There were also no differences in renal
remissions (54 vs 71%, respectively) or renal flares (29 vs
27%, respectively). The shorter regimen had less toxicity with
fewer and less severe infections.
This study provides good support for a shorter duration
and lower total dose of CYC for induction therapy for
proliferative LN. Limitations of the Euro-Lupus trial include
a population with relatively milder renal disease than in some
other studies (mean creatinine 1–1.3 mg/dl; mean proteinuria
2.5–3.5 g/day for both groups). Moreover, almost 85% of the
patients were Caucasian. In virtually every clinical study,
African-Americans fare worse than non-Blacks and this racial
factor is a strong independent risk for progressive renal
disease.13–17 Nevertheless, the ‘Euro-Lupus regimen’ is an
option for some patients with proliferative LN, in particular,
Caucasians with less severe renal injury. In addition, the
study confirms that the sequential use of CYC and AZA is a
viable strategy to reduce toxicity without compromising
overall efficacy.
Recently, MMF has emerged as a promising alternative
therapy for both induction and maintenance treatment for
LN. Extensively used in organ transplantation, MMF has also
been used in a variety of immune- and non-immune-
mediated renal diseases. Mycophenolic acid (MPA), the
active metabolite of MMF, is an inhibitor of the crucial
enzyme involved in the de novo synthesis of guanosine
nucleotides.18,19 As lymphocytes do not possess a salvage
pathway for the generation of these nucleotides, MMF results
in selective blockade of B- and T-cell proliferation. Unlike
CYC, MPA has little impact on other tissues with high
proliferative activity (i.e. neutrophils, skin, intestine, bone
marrow), which possess a salvage pathway for nucleotide
synthesis. This accounts for its more favorable toxicity
profile. In addition, MMF appears to have a variety of anti-
inflammatory actions that are independent of its effect on
cell-mediated immunity: (1) MPA may limit glomerular
injury, progressive renal scarring, and fibrosis by inhibiting
proliferation of mesangial cells and myofibroblast differentia-
tion;20,21 (2) MPA may limit lymphocyte migration into renal
tissue by inhibiting the glycosylation (and consequently the
affinity) of adhesion molecules expressed by lympho-
cytes,22,23 and (3) MPA appears to diminish renal cortical
expression of the inducible isoform of nitric oxide synthase
(iNOS),24 which has been implicated in the pathogenesis of
renal injury in LN. Moreover, there is evidence to suggest that
mycophenolate helps to retard the development of athero-
sclerosis. These properties and the potential to suppress both
upstream and downstream inflammatory events make this
medication an attractive therapy for treating LN.
Murine studies,25,26 numerous case reports, and small
uncontrolled series all suggested potential therapeutic value
of MMF in SLE.27–29 Recently, a number of major controlled
trials have compared the efficacy of MMF to CYC in
induction treatment for proliferative LN.
The first of such trials by Chan et al.30 randomized 42
patients with DPLN to 6 months of induction with MMF
(2 g/day) or oral CYC (2.5 mg/kg/day), both with concurrent
oral prednisolone. During the maintenance phase, those in
the MMF arm continued the drug at a reduced dose (1 g/day)
and those in the CYC arm switched to AZA (1.5 mg/kg/day)
for 6 months. At 12 months, there were no differences in
complete remissions (CR), partial remissions (PRs), or
relapses. There were also no significant differences in other
parameters, including serum creatinine (Scr), complement,
albumin, and 24 h urine protein. Adverse events were more
common in the CYC group, although the rate of infectious
complications was not statistically different. The study was
extended to a period of over 5 years with enrollment of an
additional 22 patients.31 After a median follow-up of 63
months, there was no difference in CR or PR. A total of 6.3%
in the MMF group and 10.0% of CYC-AZA-treated patients
showed doubling of baseline creatinine during follow-up
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(P¼ 0.667). Four patients in the CYC-AZA group but none
in the MMF group reached the composite end point of end-
stage renal disease or death (P¼ 0.06). At long-term follow-
up, there was a similar rate of relapse and relapse-free
survival in both groups. Significantly, fewer patients admi-
nistered MMF developed infections requiring hospitalization.
In addition, leukopenia was only observed with CYC, the
only two deaths were in the CYC group, and amenorrhea
was more frequent with cytotoxic therapy (36 vs 3.6%,
respectively).
The authors concluded that induction treatment with
MMF was as effective as oral CYC, but with fewer side effects.
This trial also suffers from limitations. It included only
Chinese patients and, clearly, no African-Americans. Patients
with some poor prognostic indicators including newly
diagnosed DPLN, high Scr, and substantial glomerular and
tubulointerstitial disease were also excluded from the study.
Nevertheless, the study was well performed, randomized, and
had long-term follow-up data. Certainly in the population
studied, a strong argument can be made for use of MMF
as induction therapy for many International Society of
Nephrology class IV patients.
In another trial from China, Hu et al.32 compared the
efficacy of 6 months of MMF to conventional i.v. CYC for
induction therapy in 46 patients with DPLN. Patients
randomized to MMF had greater reduction of proteinuria,
lupus serologic activity, urinary sediment activity, and glomer-
ular immune deposits on repeat biopsy while experiencing
fewer side effects.
A more recent study by Ginzler et al.33 addressed the issue
of efficacy of MMF induction in a high risk, multi-racial,
American population in which 56% of the patients were
African-American. This study was designed as an equivalency
study. In this multi-center, prospective trial, 140 patients (the
majority with class IV LN) were randomized to standard six
monthly pulses of i.v. CYC or MMF (target dose 3 g/day) in
conjunction with a tapering dose of corticosteroids. The
study allowed crossover at 3 months for treatment failure or
toxicity. No maintenance regimen was specified after the
induction. The primary end point was CR at 24 weeks
defined as normal values of Scr, absence of proteinuria, and
normal urine sediment. PR was defined as 450% improve-
ment in all renal parameters. At the 6-month end point, in an
intention-to-treat analysis, there were fewer treatment fail-
ures, and more complete and complete plus PRs with MMF
(22 and 52%, respectively) compared to CYC (4 and 30%,
respectively). Crossover to the alternate arm was more
common with CYC than with MMF (20 vs 8%, respectively).
MMF was also associated with a lower incidence of severe
infections, and in general fewer, milder side effects. At 3-year
follow-up, there were no significant differences in time to
first renal flare, renal failure, or death. However, all tended to
be lower in the MMF group.
The authors concluded that induction therapy with MMF
was superior to i.v. CYC in inducing remissions of LN and
was better tolerated. A major limitation of this study is the
short duration of follow-up. Longer-term studies are needed
to determine the relapse rate and long-term renal survival in
this population. This study also did not compare MMF to
CYC with steroid pulses, which many clinicians routinely use
for severe LN. The early crossover design may have resulted
in premature designation of treatment failures. In addition,
patients with rapidly progressive renal failure, ARF, and Scr
43 mg/dl or CrClo30 cc/m were excluded. Finally, although
the groups were matched for WHO histologic class on biopsy,
it is unknown whether patients with a greater percentage of
crescents or interstitial fibrosis will respond equally to the
two treatment regimens. Despite these caveats, this study
adds significant proof of efficacy for MMF induction therapy
in at least some high-risk patients, including African-
Americans, with proliferative LN. A new, multi-center,
international trial randomizes 350 patients with severe LN
to either 6 months of MMF vs. i.v. CYC. Patients with a
satisfactory response in both groups at 6 months will
subsequently be randomized to either MMF or AZA
maintenance therapy (Aspreva Lupus Management Study/
ALMS)(Appel G et al., J Am Soc Nephrol 2005: 16: 528A;
abstract).
It should be noted that at the time of these trials and even
currently, there remain major questions about the optimal
regimen, duration, and dosage of MMF therapy in LN.
Dosing was initially adapted from transplantation regimens
of fixed doses in combination with at least one other
immunosuppressive drug. Drug levels have not typically been
measured in lupus trials, despite the fact that the pharma-
cokinetics of mycophenolate shows large individual varia-
bility. Thus, further investigations will be necessary to obtain
optimal target treatment ranges that allow tailoring of
therapy in individual patients.
MAINTENANCE TREATMENT
Despite successful induction of proliferative GN, relapses are
common, ranging from 10 to 65%.34,35 With each relapse,
continued renal damage can adversely affect long-term renal
survival36 and the treatment of these relapses adds to the
toxicity burden. The major challenge of maintenance therapy
is avoiding relapses and smoldering disease while minimizing
the attendant side effects of continued therapy. The optimal
treatment and duration of maintenance therapy remains
controversial.
A recent trial by Contreras et al.37 sheds light on the
relative efficacy of maintenance regimens using either MMF,
AZA, or continued i.v. CYC in severe LN. The high-risk study
population included 59 patients, predominantly African-
Americans and Hispanics. The majority had diffuse prolif-
erative disease with mean Scr 1.6 mg/dl and urine protein/
creatinine ratio 45. After induction therapy with 4–7
monthly pulses of i.v. CYC, 83% of the patients achieved
remission and were then randomized to one of three
maintenance regimens: i.v. CYC pulses (every third month)
or AZA (1–3 mg/kg/day) or MMF (0.5–3 gm/day) for
approximately 2 years. Fewer patients treated with AZA
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and MMF group reached the primary end points of death
and CRF compared to the CYC group. Relapse-free survival
was higher with MMF (78%) and AZA (58%) compared to
i.v. CYC (43%). Mortality was increased with i.v. CYC
compared to both oral agents. Complications of therapy
including hospitalizations, amenorrhea, infections, and
gastrointestinal problems were significantly lower with
MMF and AZA.
The authors concluded that maintenance therapy with
either MMF or AZA was superior to i.v. CYC. There are
several limitations with this study. Some patients did not
achieve remission at the end of the induction phase with i.v.
CYC, which may be attributable to the large percentage of
Hispanics and Blacks in the study. Patients with rapidly
progressive and crescentic disease were excluded. Never-
theless, the favorable response to AZA and MMF compared
to continued every third month i.v. CYC strongly suggests a
role for the less toxic oral agents in maintenance therapy.
In light of these results and the Euro-Lupus trial, a
randomized multi-center trial (MAINTAIN Nephritis Trial)
conducted by The European Working Party on Systemic
Lupus Erythematosus is currently underway to compare the
efficacy and toxicity of MMF and AZA as remission-main-
taining treatment for proliferative LN following induction
with a short course of i.v. CYC.
BIOLOGICS/IMMUNOMODULATION
Over the last two decades, increasing understanding of the
complex pathologic mechanisms underlying SLE in combi-
nation with accelerating advances in molecular and cellular
immunology have paved the way for development of biologic
therapies for LN. In contrast to the global effects of
conventional immunosuppressants, these novel agents inter-
fere with specific pathways responsible for the pathologic
autoimmune responses.
Although the pathophysiology of SLE is complex, B-cell
hyperactivity and autoantibody production have been a
consistent feature.38–40 In addition to the production of
antibodies, B cells lead to the activation of the immune
system through antigen presentation, activation of auto-
reactive T cells, dendritic cell regulation, and production of
cytokine and chemokines. Thus, B cells represent a rational
therapeutic target in SLE. More than one therapeutic
approach to impair or delete B-lymphocytes has been
explored including the use of LJP 394 and rituximab.
LJP 394 (riquent, abetimus sodium) was the first of such
agents designed to selectively modulate autoantibody produ-
cing B cells and reduce pathologic antibodies directed against
dsDNA.41 This agent, consisting of four dsDNA helices
conjugated to an inert polyethylene scaffold, is believed to
reduce circulating autoantibodies by two mechanisms: (1)
crosslinking anti-dsDNA surface immunoglobulin receptors
on B cells leading to tolerance via anergy or apoptosis, and
(2) binding to circulating antibodies, forming small soluble
complexes that are subsequently cleared.42 In a multi-center,
placebo-controlled trial, 230 patients with LN (class III, IV,
V) were randomized to either LJP 394 or placebo for 76
weeks. Although anti-dsDNA titers decreased and C3 levels
increased with therapy, time to renal flare and the number of
renal flares was not significantly different in the two groups.
In a subset analysis, time to renal flare was prolonged in
patients who had antibodies with high-affinity binding to the
epitope of LJP 394.43 However, a subsequent trial designed to
confirm the efficacy of LJP 394 specifically in patients with
these high-affinity antibodies failed to demonstrate a
significant difference in renal flares between LJP and placebo.
This was likely secondary to better background immuno-
suppression, thus reducing the overall flare rate and making
it harder to show a significant benefit of a newer agent over
placebo.
Rituximab is a chimeric monoclonal antibody (mAb)
directed against CD20, a membrane-associated glycoprotein
present on B-lymphocytes, but not on plasma cells. It consists
of the variable region of a murine anti-human CD20 B-cell
hybridoma fused to human IgG1k constant region. Although
the mechanisms whereby rituximab achieves its effects
remain incompletely understood, it seems to involve a
combination of complement-dependent cell lysis, FcRg-
dependent antibody-dependent cell-mediated cytotoxicity,
and induction of apoptosis.44 Since its approval as treatment
for B-cell lymphomas, rituximab has been successfully
exploited for the off-label treatment of a wide variety of
autoimmune diseases,45–52 transplant rejection,53,54 and
certain glomerular diseases.55–60 With its extensive use in
the clinical setting, rituximab has accumulated an excellent
safety and tolerability profile.61,62
There is growing evidence to suggest that rituximab can
also be effective therapy in LN. Numerous case reports and
several open-label, uncontrolled trials describe the efficacy of
rituximab in lupus patients with a variety of renal and extra-
renal manifestations refractory to conventional immuno-
suppression.62–68 The patients were highly heterogeneous
with respect to disease severity, organ involvement, prior
therapy, concomitant treatment, and the specific regimen of
rituximab used, thus making it difficult to fully evaluate the
role of B-cell depletion for LN.
A small open-label study by Sfikakas et al.69 investigated
the efficacy of rituximab exclusively in patients with LN. Ten
patients with class III or IV LN received rituximab (four
weekly infusions of 375 mg/m2) with oral prednisolone
(0.5 mg/kg/day for 10 weeks followed by a slow taper). Eight
patients achieved PR within 1–4 months, and five of these
patients subsequently achieved CR after a median of 4
months. B-cell depletion lasted a median of 5 months. Three
patients relapsed but CR was sustained in four patients at 12
months despite B-cell repletion. This suggests that total B-cell
levels may not accurately reflect the overall immunologic
impact of therapy. Although reductions in levels of
antinuclear antibody and anti-dsDNA autoantibodies
were observed in all patients, serologic improvement did
not correlate with clinical response. This suggests that
remission of nephritis was not only related to a decrease in
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autoantibody production. Although these results are en-
couraging, other investigators have reported more modest
clinical benefits with rituximab. Furthermore, it appears that
many of the patients, while ‘nephritic’, did not have highly
active nephritis, and as such, the clinical improvement may
be achievable with the long duration of steroids. Never-
theless, the results of this and previous trials suggest a
promising role for rituximab in the treatment of SLE. A
multi-center prospective randomized placebo-controlled trial
(LUNAR by Genentech) is currently underway to evaluate the
additive benefit of rituximab to MMF for induction therapy
and maintenance in patients with proliferative LN.
Despite widespread use of rituximab, there is still much to
learn about the effects of this medication, particularly in
patients with lupus whose response to this medication may
be different compared to patients with other diseases. Further
studies are warranted to evaluate the mechanisms whereby
B-cell depletion improves disease, the relative sensitivities of
the B-cell subsets to depletion, the role of the unaffected B-
cell subsets (i.e. plasma cells), the kinetics of repopulation,
the quality of reconstituted B cells, as well as the relevance of
FcR polymorphisms and complement deficiency to response
to therapy. There is evidence to suggest that the clinical
benefits of rituximab may be explained by mechanisms
independent of B-cell count and autoantibody produc-
tion.62,69,70 Clearly, patients can maintain remissions for
extended periods of time, despite recovery of CD19 and
CD20 cells. Indeed, following B-cell depletion, marked
changes in several aspects of the immune response have
been observed in lupus patients including downregulation of
CD40 and CD80 on B cells as well as alterations in the
activation potential of T helper cells (decreased CD40L and
CD69).69,71 These findings need to be validated in larger
studies. Correlating such changes in immunologic responses
with rituximab-induced clinical benefits will facilitate devel-
opment of optimal therapeutic regimens that incorporate
rituximab and may also uncover pathways that can be
targeted simultaneously or consecutively with other agents.
Another promising therapeutic strategy for the treatment
of LN is blockade of the interactions between B and T cells
and is based on the observation that T-cell activation requires
two signals.72,73 The first signal is provided when the antigen
is presented to the T-cell receptor in the context of major
histocompatibility complex class II molecules on antigen-
presenting cells. The second signal is provided by the
interaction of costimulatory molecules on T-lymphocytes
and antigen-presenting cells.74,75 Disruption of this second,
nonspecific costimulatory signal results in the interruption of
the (auto)immune response, leading to a state of immune
unresponsiveness or anergy. There is much evidence to
suggest that aberrant expression of costimulatory molecules,
dysregulation of costimulatory receptor–ligand interactions,
and resultant T-cell-dependent expansion of autoreactive B
and T cells contribute to loss of self-tolerance and develop-
ment of SLE.76–81 The CD40:CD40L and CD28:B7 family of
molecules are considered important costimulatory elements
in this regard.82–90 This has provided the rationale for the
development of therapies that disrupt these costimulatory
pathways.
Impressive results with anti-CD40L therapy in lupus-
prone mice91 led to clinical trials using two different
humanized anti-CD40L mAbs (BG9588 and IDEC-131) in
patients with SLE. However, the anti-CD40L mAb approach
in human lupus has not yet been fruitful. An open-label trial
of BG9588 (riplizumab) showed reduction of serologic lupus
activity and improvement of renal function in patients,92 but
the high prevalence of life-threatening thromboembolic
events led to the premature termination of trials with this
agent. IDEC-131 also did not prove to be clinically effective
in human SLE despite being safe and well tolerated.93,94
One of the most prominent and well-characterized T-cell
costimulatory signals is mediated through the CD28-CD80/
86 pathway, which regulates interleukin-2 production and
expression of antiapoptotic molecules, augments T-cell
proliferation, and upregulates the expression of other
costimulatory molecules.74,95–97 CD28, present on most
T cells, binds to both CD80 (B7-1) and CD86 (B7-2), which
are present on antigen-presenting cells. Cytotoxic T-lympho-
cyte antigen 4 (CTLA-4), a structural homolog of CD28, is
also expressed on the surface of activated helper cells and
plays a crucial regulatory role in T-cell response.98,99 CTLA-4
competes with CD28 for the same B7 ligands on antigen-
presenting cells, but has a higher avidity for them.100–103 The
capture of B7 by CTLA-4 antagonizes CD28-dependent
costimulation. It also provides important inhibitory signals
that permit long-term tolerance.104–108 The regulatory effects
of interrupting CD28:B7 interactions by CTLA-4 have been
exploited with the development of CTLA4-Ig, a recombinant
molecule that fuses the extracellular domain of human
CTLA-4 with the constant region of the human IgG1 heavy
chain.101,109 In humans, two preparations of CTLA4-Ig,
abatacept and belatacept, have been used clinically.110 Initial
experience with these agents in both the autoimmune and
transplant arenas has been encouraging. For example,
abatacept has been shown to be efficacious and well tolerated
in patients with active rheumatoid arthritis.111–114 A recently
completed phase II clinical trial found belatacept to be as
effective as cyclosporine in preventing acute rejection of renal
allografts.115 There is animal data to support the efficacy of
CTLA4-Ig in lupus.109,116 However, this approach has not yet
been applied in human LN. Clinical trials using these mAbs
in lupus are anticipated.
The discovery of new costimulatory molecules and
immune mediators will inevitably suggest new treatment
strategies for LN in the future. Other potential therapeutic
targets include chemokines, cytokines (i.e. interleukin-6,
interleukin-10,117 interleukin-18), B-lymphocyte stimula-
tor,118–120tumor necrosis factor-a, interferons,121–123 Toll-like
receptor124–127 adhesion molecules, and complement compo-
nents. Given the complexity of lupus, these biologic agents
will likely be used in combination with conventional therapy
(and other biologic agents) to induce remission in early
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disease and to maintain remission. One of the major
challenges to developing treatment strategies employing
biologics is understanding the interactions between these
agents and conventional immunosuppressive drugs. This is
important clinically, as immunosuppressants may abrogate,
synergize with, or not affect the function of such agents. For
example, previous studies in a rodent transplant model
showed that cyclosporine abrogated the effect of combined
blockade of CD28:B7 and CD40L:CD40 by CTLA-4Ig and
anti-CD40L mAb, respectively.128,129 Future studies will need
to address these issues.
MEMBRANOUS LUPUS NEPHRITIS
Membranous lupus nephritis (MLN) represents about 20%
of clinically significant renal disease in lupus. The course and
prognosis of MLN is variable and very different renal survival
rates have been reported for these patients in the past.130–133
This is in part related to the older WHO classification system,
which subcategorized patients with coexisting membranous
and proliferative lesions as subsets of MLN , that is, Vc or Vd.
Thus, most published series described heterogenous popula-
tions with MLN. Furthermore, the data are confounded by
variable use of steroids and other immunosuppressive agents
often given for extrarenal manifestations. Nevertheless,
proliferative changes in the presence of MLN (Vc, Vd)
confer a worse prognosis compared to pure membranous
lupus (WHO Class Va) and those with only mild mesangial
proliferation (WHO Class Vb). In one series, renal survival
was 75% for patients with Va and Vb, 59% for Vc, and 18%
for Vd patients at 5 years.130 The new International Society of
Nephrology/Renal Pathology Society classification of
LN134,135 more clearly defines histologic patterns of MLN
and clarifies the course of disease by separating the
proliferative lesions from the membranous lesions.
Optimal therapy of pure MLN is uncertain. Controlled
clinical treatment trials are limited and most studies are small
uncontrolled series or retrospective analyses.136–145 Corticos-
teroids in combination with several immunosuppressive
agents including cyclosporine, chlorambucil, CYC, AZA,
and MMF have been evaluated. Table 1 summarizes the
results of several recent retrospective and uncontrolled trials.
One randomized controlled trial from the National Institutes
of Health evaluated therapies for MLN (Austin H et al. J Am
Soc Nephrol 2004; 15:54A; abstract). In this trial, 42 patients
with WHO Class Va and Vb LN were randomized to either
intermittent pulse CYC, cyclosporine, or oral prednisone for
12 months. Baseline mean proteinuria was 5.8 g/day, serum
albumin was 2.7 g/dl, and inulin clearance of 85 ml/min.
There were more CRs and PRs with CYC and cyclosporine
treatment arms compared to prednisone. Cyclosporine led to
more rapid remissions than CYC, but relapses were also more
frequent after cyclosporine was discontinued. Ten patients
Table 1 | Retrospective and uncontrolled treatment trials for MLN
Author
Year
Type of study Therapy
No. of
patients
Mean follow-
up (months) Results/comments
Hu et al.142
2003
Retrospective
CsA+prednisone 24 1678.4 CR: 52%
PR: 43%
Relapse: 33% after withdrawal CsA
Moroni et al.141
1998
Retrospective
Chlorambucil+methylprednisolone alternating
every month for 6 months (n=11) vs.
Methylprednisolone (n= 8)
19 83759 Corticosteroids+chlorambucil:
CR: 63%
PR: 36%
Relapse: 9%
Corticosteroids alone:
CR: 37%
PR: 12%
Relapse: 87%
Mok et al.143
2004
Open label
AZA+prednisone  12 months;
Indefinite maintenance: low-dose
prednisone and AZA
38 90759 CR: 67%
PR: 22%
Relapse: 19% after mean 90 months
Renal function: 13% had decline of
CrCl; none had doubling of Scr
Chan et al.140
1999
Uncontrolled
Sequential therapy:
Induction: oral CYC 6 months +
prednisolone;
Maintenance: AZA
20 73.5748.9 CR: 55%
PR: 35%
Relapse: 40% after mean 47 months
Renal function: remained stable
Spetie et al.145
2004
Uncontrolled
MMF (6 months)+prednisone +
aggressive BP and lipid control with ACEI and/
or ARB + statin
13 1678 CR: 69%
PR: 15%
(CsA: cyclosporine A; CYC: cyclophosphamide; AZA: azathioprine; MMF: mycophenolate mofetil; CR: complete remission; PR: partial remission; ACEI: angiotensin-converting
enzyme inhibitor; ARB: angiotensin receptor blocker).
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who failed to respond to prednisone or cyclosporine or who
relapsed after cyclosporine were subsequently treated with
CYC and eight achieved remission (six PR, two CR). Thus,
the authors concluded that i.v. CYC and cyclosporine are
more effective than prednisone alone in inducing remission
of proteinuria, but i.v. CYC leads to more sustained
remissions.
The role of MMF in MLN is unclear. The response to
MMF was poor in one series by Kapitsinou et al.144 in which
18 patients with different classes of LN were treated with
MMF. All four treatment failures were in those with a
primarily membranous picture. Other investigators have
reported more favorable results with MMF (Table 1).139,145,146
In the previously described multi-center study by Ginzler
et al.,33 27 of the 140 patients had pure membranous lupus.
Subgroup analysis of 16 patients who completed 24 weeks of
induction therapy revealed that response to MMF was similar
to i.v. CYC with no difference in rates of PR or CR, changes
in SCr, albumin, urinary protein, or serologies between the
two groups at follow-up (Radhakrishnan J et al. J Am Soc
Nephrol 2005;16:8A; abstract).
Treatment of MLN should be based on severity of disease.
Patients with pure MLN with subnephrotic levels of
proteinuria and preserved glomerular filtration rate have a
good renal prognosis and consideration may be given to a
short course of cyclosporine with low-dose corticosteroids
along with inhibitors of the renin–angiotensin system and
statins. For fully nephrotic patients and those at higher risk of
progressive disease, based on the available evidence, options
include cyclosporine, monthly i.v. pulses of CYC, MMF, or
AZA plus corticosteroids. Patients with mixed membranous
nephropathy and proliferative disease are treated in the same
way as those with proliferative disease alone.
ADJUNCTIVE THERAPY
With the advent of more potent and safer immunosuppres-
sive regimens, death from uncontrolled lupus activity is
uncommon and patients live longer. Accelerated athero-
genesis and coronary vascular disease are now a major cause
of later mortality.147 Possible risk factors for this include
hypertension, hyperlipidemia, nephrotic syndrome, pro-
longed corticosteroid use, antiphospholipid antibody syn-
drome, and in some, the added vascular risks of CKD.148,149
This underscores the importance of aggressive management
of these modifiable risk factors. Although little data are
available specifically for patients with LN, it appears prudent
to apply the knowledge from the general population with
CKD to this patient subset. Thus, tight blood pressure
control (o130/80), the use of angiotensin-converting
enzyme inhibitors and/or angiotensin receptor blockers,
and correction of dyslipidemia are recommended. In
addition, measures to prevent glucocorticoid-induced osteo-
porosis should be taken, including use of calcium, vitamin D
supplements, and bisphosphonates when necessary.
CONCLUSION
The past few years have been an exciting period of more
rigorous investigation to find new therapeutic regimens for
Induction
MMF (2–3 g/day) × 6 months
Cyclophosphamide (CYC)
Standard: 0.5–1 g/m2 i.v. monthly × 6 or
 Euro-lupus : 500 mg i.v. q 2 weeks × 6 or
 
∗Oral 1–3 mg/kg/day
Methylprednisolone  i.v. 1 g × 3 days and/or
p.o. Prednisone 1 mg/kg, then slow taper 
Maintenance
Supportive measures
ACE inhibitor/ARB and 
Bone health/prevention of osteoporosis and
Primary and secondary prevention of cardiovascular disease
If Resistant
Low-dose prednisone
MMF
1–2 g/day
AZA
1–2 mg/kg/day
Switch to alternate agent :CYC↔ MMF or
Add rituximab or
Add IVIG??
+
OR OR
∗see text for details regarding protocol 
+
,
,
∗
Figure 1 | Treatment options for severe proliferative LN.
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LN. This review highlights the progress that has been made so
far from recent randomized controlled trials. Figure 1
outlines an algorithm for the treatment of proliferative LN
based upon the results of these trials. Clearly, treatment plans
needs to be individualized according to clinical scenario,
degree of activity and chronicity on biopsy, tolerability,
willingness of the patients, and prior treatments. In addition,
one needs to be aware of the limitations of the studies that
lead to these recommendations in order to make appropriate
decisions regarding therapy. Hopefully, future studies, some
of which are already in progress, will help refine these
recommendations as well as provide additional treatment
options for patients suffering from this disease.
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